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Identification of four new susceptibility loci for
testicular germ cell tumour
Kevin Litchfield1, Amy Holroyd1, Amy Lloyd1, Peter Broderick1, Je´re´mie Nsengimana2, Rosalind Eeles1,3,
Douglas F. Easton4, Darshna Dudakia1, D. Timothy Bishop2, Alison Reid5, Robert A. Huddart5, Tom Grotmol6,
Fredrik Wiklund7, Janet Shipley8, Richard S. Houlston1 & Clare Turnbull1,9
Genome-wide association studies (GWAS) have identified multiple risk loci for testicular
germ cell tumour (TGCT), revealing a polygenic model of disease susceptibility strongly
influenced by common variation. To identify additional single-nucleotide polymorphisms
(SNPs) associated with TGCT, we conducted a multistage GWAS with a combined data
set of 425,000 individuals (6,059 cases and 19,094 controls). We identified new risk
loci for TGCT at 3q23 (rs11705932, TFDP2, P¼ 1.5 10 9), 11q14.1 (rs7107174, GAB2,
P¼ 9.7 10 11), 16p13.13 (rs4561483, GSPT1, P¼ 1.6 10 8) and 16q24.2 (rs55637647,
ZFPM1, P¼ 3.4 109). We additionally present detailed functional analysis of these loci,
identifying a statistically significant relationship between rs4561483 risk genotype and
increased GSPT1 expression in TGCT patient samples. These findings provide additional
support for a polygenic model of TGCT risk and further insight into the biological basis of
disease development.
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T
esticular germ cell tumour (TGCT) is the most common
cancer in men aged 15–45 years, with over 18,000 new
cases diagnosed annually in Europe1,2. The incidence of
TGCT has approximately doubled over the last four decades in
Western Europe3, which implicates environmental or lifestyle
factors as risk determinants. However, to date, no exogenous
associations have been robustly validated4. Family and twin
studies support a strong genetic basis to TGCT susceptibility5,6,
with brothers of cases having an eight-fold increased risk of
TGCT7. Direct evidence for inherited genetic susceptibility to
TGCT has come from recent genome-wide association studies
(GWAS), which have identified a number of independent loci
influencing TGCT risk8 17. The associations identified by
GWAS have provided novel insights into the development of
TGCT, highlighting the role of genes involved in KIT/KITLG
signalling, telomerase function, microtubule assembly and DNA
damage repair18.
The over-representation of association signals in GWAS after
accounting for known risk loci supports the existence of
additional risk loci for TGCT. To identify new risk variants for
TGCT, we have performed a GWAS meta-analysis, genome-wide
imputation and large scale replication genotyping. Our combined
data set comprises over 25,000 individuals and48 million single-
nucleotide polymorphism (SNPs), the largest study of its kind to
date for TGCT. We report the identification of four new risk loci
for TGCT.
Results
Association analyses. We adopted a three-stage design, incor-
porating GWAS discovery, custom array follow-up and replica-
tion genotyping (Fig. 1). Genome-wide discovery (stage 1) was
performed in 986 TGCT cases and 4,946 controls for 307,291
SNPs, as previously described10,16. The most strongly associated
SNPs from stage 1 were included on a custom consortia array
(iCOGs) and follow-up genotyping (stage 2) was conducted in an
additional 1,064 cases of TGCT and 10,082 controls, as previously
described12,19. Meta-analysis was then conducted on 57,066 SNPs
overlapping between stages 1 and 2. To achieve dense genome-
wide coverage, we retrospectively imputed unobserved genotypes
(stage 1a) using our discovery GWAS data set and the 1000
genomes project reference panel. Results from meta-analysis and
imputation were filtered to identify 20 SNPs at 12 loci with
promising signs of association on the basis of the following
criteria: (i) Po5.0 10 4, (ii) SNPs mapping to distant loci not
previously associated with TGCT risk, (iii) in silico look-up in a
Scandinavian GWAS data set comprising 1,326 cases and 6,687
controls genotyped using Human OmniExpressExome-8v1
Illumina arrays (Po0.1, ref. 17), (iv) consistent odds ratio (OR)
effect sizes and allelic frequencies across all data sets. For these 12
loci, we conducted a replication study (stage 3), genotyping an
additional 4,009 TGCT cases and 4,066 controls. Genotyping was
successful for SNPs at 10 of the 12 loci. All the case and control
samples were from the UK and formed unique sets, with no
individuals overlapping between stages.
We tested association between each SNP and TGCT risk at
each stage using the 1 d.f. trend test, with data from stages 1 and 2
being adjusted for six principal components. Inflation in the test
statistics was observed at only modest levels (lo1.05, l1000o1.02
across all the stages). A combined fixed-effects meta-analysis was
performed for SNP data across all the stages, for the 10
successfully genotyped loci. In the combined meta-analysis,
SNPs at four novel loci attained genome-wide significance
(Po5.0 10 8; Table 1, Fig. 2). First, rs11705932 (OR¼ 1.18,
confidence interval (CI)¼ 1.09–1.28, P¼ 1.5 10 9) which lies
within a 240 kb region of linkage disequilibrium (LD) at 3q23,
containing genes TFDP2 and ATP1B3. Second, rs7107174
(OR¼ 1.26, CI¼ 1.16–1.37, P¼ 9.7 10 11) which maps
to intron 1 of GAB2 (11q14.1), in a 227 kb region of LD to
which USP35 also localizes. Third, rs4561483 (OR¼ 1.09,
95% CI¼ 1.02–1.16, P¼ 1.6 10 8) intronic to BCAR4
(16p13.13) within a 145 kb LD block also containing RSL1D1,
GSPT1 and TNFRSF17. Finally, rs55637647 (OR¼ 1.17,
CI¼ 1.09–1.24, P¼ 3.4 10 9) mapping within intron 1 of
ZFPM1 (16q24.2), within a 40 kb LD block.
We examined for evidence of genotype-specific effect for
rs11705932, rs7107174, rs4561483 and rs55637647, however, no
significant departure from a log-additive model was seen. We
additionally tested for interaction between rs11705932,
rs7107174, rs4561483 and rs55637647 and SNPs at previously
identified risk loci for TGCT (Supplementary Table 2). Some
evidence of interaction between rs11705932 and previously
reported SNP rs12699477 (at 7p22.3) was shown (P¼ 0.003),
albeit nonsignificant after correcting for 84 tests.
Functional analysis of the four new TGCT SNPs. To gain
insight into the biological basis of associations at rs11705932,
rs7107174, rs4561483 and rs55637647, we conducted expression
quantitative trait loci (eQTL) analysis using RNA-seq expression
Stage 2: Custom follow-up (iCOGs)
57,066 SNPs
1,064 Cases / 10,082 controls
Stage 3: Replication genotyping
10 SNPs
4,009 Cases / 4,066 controls
Stage 1: GWAS discovery
307,291 SNPs 
986 Cases / 4,946 controls
Total:
Cases = 6,059
Controls = 19,094
Stage 1A:
Imputation
8.9 Million
SNPs
Figure 1 | Study design, genotyping conducted over three stages, comprising non-overlapping samples from the UK. Imputation was performed on
stage 1 GWAS data set.
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Table 1 | Summary of results across all genotyping stages.
SNP* Chr. Allelesw RAFz Stage 1/1a—GWAS/Imputation Stage 2—iCOGs Stage 3—Replication Combined
ORy (95% CI) Ptrend
|| OR (95% CI) Ptrend OR (95% CI) Ptrend Pmeta
z Phet
# I2 Het**
rs11705932 3 T/C 0.80 1.21 (1.07-1.37) 2.7 10 3 1.22 (1.08–1.38) 1.2 10 3 1.18 (1.09–1.28) 3.4 105 1.5 109 9.1 10 1 0
rs147686985 3 G/C 0.02 1.80 (1.33–2.44) 2.6 10 6 — — 1.06 (0.84–1.33) 6.4 10 1 4.0 10 1 9.4 10 3 85
rs13062518 3 T/C 0.43 1.21 (1.09–1.33) 2.6 104 1.14 (1.04–1.25) 6.1 10 3 1.06 (1.00–1.13) 6.3 10 2 9.6 10 2 1.0 104 91
rs16873802 5 T/C 0.03 1.76 (1.33–2.32) 3.0 10 5 — — 1.06 (0.87–1.29) 5.4 10 1 2.9 10 2 1.1 10 2 85
rs6927322 6 T/G 0.04 1.55 (1.27–1.89) 1.2 10 5 — — 1.24 (1.08–1.43) 3.2 10 3 6.1 10 6 1.1 10 1 61
rs13279707 8 T/C 0.05 1.58 (1.29–1.92) 7.5 10 6 1.28 (1.06–1.56) 1.1 10 2 1.06 (0.92–1.22) 4.2 10 1 2.7 10 3 1.0 104 89
rs7107174 11 T/C 0.15 1.14 (1.01–1.30) 4.2 10 2 1.21 (1.07–1.36) 2.0 103 1.26 (1.16–1.37) 4.8 108 9.7 10 11 4.6 10 1 0
rs4561483 16 A/G 0.35 1.22 (1.10–1.35) 1.3 104 1.20 (1.10–1.32) 1.1 104 1.09 (1.02–1.16) 8.1 10 3 1.6 108 9.7 10 2 57
rs3850997 16 T/G 0.33 1.17 (1.06–1.30) 2.5 10 3 1.18 (1.07–1.30) 7.6 104 1.06 (1.00–1.13) 6.9 10 2 1.0 10 5 1.2 10 1 54
rs55637647 16 G/C 0.37 1.21 (1.10–1.34) 6.5 10 5 — — 1.17 (1.09–1.24) 2.7 106 3.4 109 5.2 10 1 0
SNPs highlighted in bold achieved genome-wide significance.
*dbSNP rs number.
wAlleles (risk allele is underlined).
zRisk allele frequency.
yOR: per allele odds ratio.
||Ptrend: P value for trend, via logistic regression.
zPmeta: P value for fixed effects meta-analysis.
#Phet: P value of heterogeneity between studies.
**I2 heterogeneity index (0–100).
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Figure 2 | Regional plots of the four new TGCT loci. (a–d) Shown by triangles are the  log10 association P values of genotyped SNPs, based on meta-
analysis (three-stage data for sentinel SNPs) and stages 1/2 for all other SNPs. Shown by circles are imputed SNPs at each locus, which were imputed from
the stage 1 data set. The intensity of red shading indicates the strength of LD with the sentinel SNP (labeled). Also shown are the SNP build 37 coordinates
in mega-bases (Mb), recombination rates in centi-morgans (cM) per mega-base (Mb) (in light blue) and the genes in the region (in dark blue). The
zoomed-in section displays the exact LD block for each SNP, with the sentinel SNP marked with a red triangle, any significant regulatory markers denoted
with a red circle and the chromHMM prediction states coloured as per the legend.
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and Affymetrix 6.0 SNP/exome sequencing data on 150 TGCT
patients, which is publicly available through the cancer genome
atlas (http://cancergenome.nih.gov/). Where the data for our
sentinel SNP was not available, we analysed data for the best two
proxy SNPs (defined as those with the highest r2 correlation) for
which data were available, namely: 3q23 (sentinel SNP
rs11705932), 11q14.1 (rs2450140, r2¼ 0.88 and rs11237477,
r2¼ 0.86), 16p13.13 (rs2075158, r2¼ 0.78 and rs2018199,
r2¼ 0.79) and 16q24.2 (rs3859027, r2¼ 0.91 and rs12597021,
r2¼ 0.87). Each of the nine genes (ATP1B3, BCAR4, GAB2,
GSPT1, RSL1D1, TFDP2, TNFRSF17, USP35 and ZFPM1) within
the LD blocks at the four new risk loci were tested for evidence of
an eQTL. No significant associations were identified at 11q14.1,
3q23 or 16q24.2. However, a statistically significant association
was found at 16p13.13, between genotype and expression of
GSPT1 (proxy SNPs rs2075158 P¼ 5.1 10 4, rs2018199
P¼ 5.9 10 4), which remained significant after correction for
multiple testing (Supplementary Table 1). Both SNPs rs2075158
and rs2018199 can be considered good proxy markers, having
high r2 correlation with and closely comparable minor allelic
frequencies to, the sentinel SNP. Homozygosity for the risk allele
at rs2075158 was associated a with 35% increase in GSPT1
expression compared with the reference homozygote genotype
(Supplementary Fig. 1).
We used HaploReg20 and Roadmap Epigenome Mapping
Consortium data on enhancer elements to examine whether
rs11705932, rs7107174, rs4561483 and rs55637647 or their
proxies (that is, r240.8 in 1000 Genomes CEU reference panel)
lie at putative transcription factor binding/enhancer elements.
In addition, we analysed GERP (Genomic Evolutionary Rate
Profiling) scores to assess sequence conservation (Supplementary
Data). At 11q14.1, which contains GAB2, there is evidence of
strong evolutionary conservation, with 21 correlated SNPs having
GERP score 42.0, the strongest of which is SNP rs2511156,
which is in almost perfect LD with the sentinel SNP. In addition,
multiple correlated SNPs at 11q14.1 are predicted to be in strong
enhancer regions, with four SNPs located within DNase
hypersensitivity sites in the TGCT specific cell line NT2-D1.
Furthermore, 10 correlated SNPs at 11q14.1 alter the binding
motif of embryonic transcription factor NANOG, a pluripotency
factor strongly implicated in TGCT development21. At 16q24.2,
the sentinel SNP rs55637647 is conserved and EGR1 binding, an
early growth response transcription factor linked to infertility and
differential expression in germ cell tumours22,23, was also
reported within the LD block. No evidence of evolutionary
conservation was seen for any SNPs at either 3q23 or 16p13.13
risk loci; however, both loci feature SNPs mapping to predicted
enhancers. In addition, the significantly associated eQTL SNP at
16p13.13 (rs2075158) lies within a predicted strong active
promoter site. Both 3q23 and 16p13.13 risk loci also have SNPs
shown to alter the binding motif of SOX family transcription
factors, which regulate germ cell development and sex
determination. In addition, the protein STAT3, which is critical
for embryonic development and is expressed in the developing
spermatids of adult testis24, binds to the locus at 3q23.
Finally, using matched tumour/normal exome sequencing data
from our recent study of 42 UK TGCT patients25, we analysed
somatic mutational events occurring in genes ATP1B3, BCAR4,
GAB2, GSPT1, RSL1D1, TFDP2, TNFRSF17, USP35 and ZFPM1.
The only recurring event, seen in 45% of tumours was a copy
number deletion encompassing GAB2 and USP35 at 11q14.1
found in 7% of tumours. These deletions were large, spanning up
to 55Mb.
Pathway analysis. We performed gene set enrichment analysis to
determine whether any of the genes mapping to our four newly
identified loci reside in pathways already enriched with TGCT
SNPs. Using the i-GSEA4GWAS algorithm26 on stage 1 data, a
total 31 pathways showed enrichment in the analysis of genome-
wide association data for TGCT (FDR o0.1; Supplementary
Table 3). Five pathways that were of note were those involved in
sex determination, centrosome cycle, apoptosis, KIT/KITLG
signalling and DNA damage repair, further substantiating
existing evidence linking these gene sets to TGCT17,18,27.
Focusing on these five pathways, genes at three of the new loci
feature (see Supplementary Fig. 2). The first related pathway
involves GAB2 at 11q14.1, a member of the GRB2-associated
binding protein (GAB) gene family, which associates with KIT
forming a critical part of the KIT/KITLG signalling cascade28. The
second related gene is ZFPM1 at 16q24.2, linked to sex
determination, with ZFPM1 being shown to specify germ cell
differentiation as sperm rather than oocytes in Caenorhabditis
elegans29. Both ZPFM1 and its paralogue ZPFM2 regulate the
activity of GATA family of transcription factors, which are
abundantly expressed from the onset of human gonadal
development and found in multiple cell lineages of the
testis30,31. The third related gene is GSPT1 at 16p13.13, which
is a documented determinant of apoptosis32.
Personalized risk profiling. The OR effect sizes of TGCT SNPs
have been among the highest reported in GWAS of any cancer
type33, hence suggesting a potential clinical utility for
personalized risk profiling. To assess this potential, we
constructed polygenic risk scores (PRS) for TGCT, considering
the combined effect of all risk SNPs modelled under a log-normal
relative risk distribution, as implemented for other cancer
types34 36. Using this approach for the four new risk loci,
together with all existing risk SNPs (Supplementary Table 2), the
men in the top 1% of genetic risk had a 10.4-fold relative and
5.2% lifetime risk of TGCT (Fig. 3).
12
10
8
6
4
2
0
50%
50% 60% 70% 80% 90%
45%
40%
40%
35%
30%
30%
25%
20%
20%
15%
10%
10%
5%
0%
5.2%
0%
10.4
TGCT relative versus lifetime risk, by PRS percentile
R
el
at
ive
 r
is
k 
(vs
 po
pu
lat
ion
 m
ed
ian
)
Population, ordered by genetic risk
Lifetime risk Relative risk
Ab
so
lu
te
 lif
e
tim
e 
ris
k
Figure 3 | Population distribution of polygenic risk scores for TGCT,
ordered from lowest to highest genetic risk (risk is relative to population
median risk). Relative risk is plotted as a blue line, lifetime risk as red bars.
Values are marked for individuals in the top 1% of highest genetic risk.
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Discussion
Here we have genotyped the largest number of TGCT cases to
date, identifying four novel TGCT susceptibility loci at 3q34,
11q14.1, 16p13.13 and 16q24.2. We additionally performed
TGCT cell type-specific eQTL analysis of these loci, identifying
a possible cis-regulatory effect on GSPT1 expression at 16p13.13.
Aside from the detailed functional work undertaken by Bond
et al. exploring the mechanism underlying the signal at 12q21
(ref. 37), this is the first statistically significant eQTL identified for
TGCT.
Of the four new loci, the functional mechanism at 16p13.13 is
most tangible, with expression of GSPT1 (G1- TO S-PHASE
TRANSITION 1) found to be upregulated in risk allele carriers.
GSPT1 is a proto-oncogene essential for the G1-to-S phase cell
cycle transition and regulates mammalian cell growth38,39.
Perhaps not surprisingly, GSPT1 has been shown to be
upregulated in multiple tumour types, including cancers of the
stomach, prostate and breast40 42. Furthermore, inherited
variants in GSPT1 have been reported to confer elevated risk of
gastric cancer41. As the sample size of available RNA-seq
expression data we used is relatively modest (n¼ 150), the
analysis of this effect in a larger data set would be of significant
interest. GSPT1 is also cited as a potential target for anticancer
therapy40, due to its role regulating cell cycle progression, a
process effectively targeted for various existing drug classes such
as mTOR pathway inhibitors.
At the second locus (11q14.1), there are competing functional
hypotheses, with strong TGCT cell type-specific evidence being
observed to suggest an influence on gene expression. Of the two
genes in LD at 11q14.1, a plausible candidate is GAB2 (GRB2-
associated binding protein 2), which encodes a docking protein
that is important in signal transduction from tyrosine kinases and
is bound by GRB2. GAB2 has been demonstrated to act as a
proto-oncogene in breast, colorectal and ovarian cancers as well
as melanoma43,44, and has been shown to be therapeutically
targetable by imatinib and dasatinib45. Our eQTL analysis did not
demonstrate a link between rs7107174 and GAB2 expression,
although this failure may be due to the imperfect correlation
between the true functional SNP and proxy markers available.
Alternatively, other functional mechanisms may underpin the
association; of particular note, a missense variant (rs2510044)
responsible for the P236M polymorphism in USP35 (ubiquitin-
specific peptidase 35) is in perfect LD with our sentinel SNP.
P236M is predicted to be pathogenic using the CONDEL
algorithm46,47. In our somatic data sets, a recurring deletion
encompassing both GAB2 and USP35 was found in 7% of
tumours; however, due to the large scale of these deletions there is
no evidence to suggest they specifically relate to the 11q14.1 locus.
At the third locus (16q24.2) ZFPM1 (zinc finger protein,
multitype 1, also known as FOG, Friend of GATA1) is the only
gene in LD with the sentinel SNP. Although we cannot exclude a
regulatory effect outside the LD block, ZFPM1 provides an
attractive functional basis for association being a regulator of the
transcription factor GATA1. ZFPM1 is expressed in human
Sertoli cells, first in the late fetal stages and then throughout
postnatal testicular development48. GATA transcription factors
were first implicated in carcinogenesis over two decades ago, and
their role in various types of leukaemia is now well established49.
In addition, GATA1 directly contributes to the silencing of KIT, a
pathway which is strongly implicated in both germline and
somatic studies of TGCT18,49. The last remaining locus (3q23)
contains genes TFDP2 (Transcription Factor DP2) and ATP1B3
(ATPase, Naþ /Kþ Transporting, Beta 3 Polypeptide). Although
eQTL analysis was not able to establish a link between rs11705932
genotype and expression of either gene, TFDP2 is a plausible
functional candidate, as expression of this gene is itself regulated
by binding of GATA1 (ref. 50). In this study, we therefore
implicate FOG/GATA1 genes in TGCT susceptibility for the first
time, highlighting a network of interlinked oncogenic pathways.
These four new loci provide further biological insight into this
tumour, as well suggesting a possible new target for TGCT
therapy, with reduced toxicity potential compared with current
treatment options. In addition, these loci add additional insights
into the pathways relevant to TGCT susceptibility, in particular,
to those related to sex determination, apoptosis and KIT/KITLG
signalling. Our genome-wide pathway analysis also highlighted
the centrosome cycle and DNA damage repair pathways,
consistent with previous studies. More extensive pathway
mapping of TGCT risk loci would be informative, in particular,
to explore pathways related to telomerase function and male germ
cell development. Both these latter two pathways are functionally
related to genes in LD with existing TGCT risk loci (see
Supplementary Table 2); however, they were not identified as
significant by the iGSEA4GWAS algorithm, possibly owing to the
imperfect nature of pathway definitions.
Our four new risk loci, together with the previously known risk
SNPs for TGCT, collectively explain 19% of the sibling risk of
TGCT. We constructed a PRS model to assess the clinical utility
of TGCT risk SNPs, which demonstrated marked power in terms
of risk discrimination, with men in the top 1% of genetic risk
exhibiting a 410-fold increased risk of the disease. However
consideration of lifetime risk highlights the rare nature of TGCT,
with high relative risks translating into only modest absolute risk.
Hence the current clinical utility of PRS-based risk stratification
may be limited in terms of population level screening; however,
targeted models (such as screening individuals at already elevated
baseline risk) could offer more immediate benefit. In addition,
discovery of additional risk SNPs may also improve clinical utility
and recent population and genomic analyses of heritability have
shown that: (i) TGCT is a highly heritable cancer (heritability
B48%), and (ii) a significant proportion of the heritability is
likely to reside within common SNPs51. It is therefore likely that
additional GWAS and meta-analyses will indeed lead to the
identification of further risk SNPs for TGCT.
In conclusion, by performing large-scale genotyping, we have
identified four novel susceptibility loci for TGCT. Our functional
analysis has identified a link between risk genotype at 16p13.13
and regulation of GSPT1 expression, as well as highlighting
plausible oncogenic candidates across the remaining loci.
Methods
Sample description. Cases with a diagnosis of TGCT were ascertained from two
studies (1) a UK study of familial testicular cancer and (2) a systematic collection of
UK collection of TGCT cases. Case recruitment was via the UK Testicular Cancer
Collaboration, a group of oncologists and surgeons treating TGCT in the UK
(Supplementary Note 1). The majority of cases included in stage 3 were sporadic
(3,941 sporadic versus 68 familial), hence sub-analysis of sporadic versus familial
effect size was not possible. The studies were co-ordinated at the Institute of Cancer
Research (ICR). Samples and information were obtained with full informed con-
sent and Medical Research and Ethics Committee approval (MREC02/06/66 and
06/MRE06/41).
Controls for the stage 1 GWAS were from two sources within the UK: 2,482
controls were from the 1958 Birth Cohort (1958BC) and 2,587 controls were
identified through the UK National Blood Service (NBS) and were genotyped as
part of the Wellcome Trust Case Control Consortium. Controls for the stage 2
genotyping were from three sources within the UK. Eight hundred and fourteen
cancer-free, male controls age o65 from the UK were recruited through the UK
Genetic Prostate Cancer Study (UKGPCS), a study conducted through the Royal
Marsden NHS Foundation Trust. A total 7,871 cancer-free controls (1,244 male)
were recruited via GP practices in East Anglia (2003–2009) as part of SEARCH
(Study of Epidemiology & Risk Factors in Cancer). A total 1,397 cancer-free female
controls from across the UK were recruited via the BBCS (British Breast Cancer
Study). Controls for stage 3 replication genotyping were taken from two studies,
the NSCCG (National Study of Colorectal Cancer Genetics)52 and the GELCAPS
(GEnetic Lung CAncer Predisposition Study)53. The NSCCG and GELCAP
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controls were partners of cancer patients with no personal history of cancer at the
time of ascertainment.
Genotyping. Genotyping for stages 1 and 2 was performed as previously repor-
ted10,12,16. In brief, stage 1 cases were genotyped on the Illumina HumanCNV370-
Duo bead array (Ilumina, San Diego, CA, USA) and controls were genotyped on
the Illumina Infinium 1.2M array. We used data on 314,861 SNPs that were
successfully genotyped on both the arrays. Stage 2 genotyping was conducted using
a custom Illumina Infinium array (iCOGS array) comprising 211,155 SNPs selected
across multiple consortia within the COGS (Collaborative Oncological Gene-
environment Study), as previously described12,19. SNPs attaining an Illumina
design score ofZ0.8 were included on the array. A total of 57,066 SNPs overlapped
with our stage 1 data set and were included in the meta-analysis. For stage 3
genotyping, we designed KASPar allele-specific SNV primers54, genotyping 20
SNPs across the 10 loci. Genotyping was conducted by external laboratory LGC
Limited, Unit 1–2 Trident Industrial Estate, Pindar Road, Hoddesdon, UK.
Quality control. Stage 1 data were filtered as follows: we excluded individuals with
(i) low call rate (o95%), (ii) abnormal autosomal heterozygosity or (iii) with
410% non-European ancestry (on the basis of multi-dimensional scaling). We
filtered out all SNPs with (i) minor allele frequency o1%, (ii) a call rate of o95%
in cases or controls or (iii) minor allele frequency of 1–5% and a call rate ofo99%
or (iv) deviation from Hardy–Weinberg equilibrium (10 12 in controls and 10 5
in cases). The final number of SNPs passing quality control filters was 307,291.
Stage 2 data filtering were conducted on the full SNP set of 211,155 SNPs on the
iCOGS array, with QC exclusions applied as follows to subjects using: (i) subjects
with overall call rate o95% or deficit/excess of heterozygosity (Po10 6),
(ii) using identity-by-state estimates based on 37,046 uncorrelated SNPs, we
identified ‘cryptic’ duplicates and related samples and the sample with the lower
call rate was excluded, (iii) we identified ethnic outliers by multi-dimensional
scaling by combining the iCOGS data with the three Hapmap2 populations using
37,046 uncorrelated markers and removed individuals with 410% non-Western
European ancestry. We included 1,064 cases and 10,082 controls in the final
analysis. Stage 2 QC was applied to the SNPs as follows: (i) discrepant calls in more
than 2% of duplicate samples across COGS consortia, (ii) call rate o95%,
MAFo1%, call rate o99% if MAF¼ 1–5%, (iii) deviation from Hardy–Weinberg
(Po10 5 in controls, Po10 12 in cases). For stage 3, of the 20 SNPs designed, 18
SNPs were successfully genotyped. From these 18 SNPs, one SNP from each of the
10 loci was selected, based on the strongest signal of association. The average call
rate across the 10 selected SNPs was 99.1% with all SNPs having a call rate of
498.5%. All SNPs had a MAF 41% and no SNP deviated from HWE at Po0.1.
Hence all 10 SNPs passed pre-specified QC metrics. Call rates were assessed for
individuals in stage 3, with 99.1% of individuals achieving a call rate ofZ90% and
95.2% with call rate of 100%. A small number of individuals (n¼ 32, 0.4%) failed
across all 10 SNPs and were excluded from the analysis.
Statistical analysis. Statistical analysis for stages 1 and 2 was performed as pre-
viously reported10,12,15,16. In brief, we tested for association between each SNP and
TGCT risk at each stage using a 1 d.f. trend test, with data being adjusted for six
principle components. Inflation in the test statistics was observed at only modest
levels, with values before adjustment for principle components being: stage 1
inflation factor (l)¼ 1.08 (equivalent to l1000¼ 1.05) and stage 2 l¼ 1.14
(l1000¼ 1.07). After adjustment for principle components: stage 1 l¼ 1.00
(l1000¼ 1.00) and stage 2 l¼ 1.04 ( l1000¼ 1.02). In stage 3, the 10 SNPs were
tested for association with TGCT risk and per-allele ORs were estimated, using
logistic regression with 1.d.f, in line with the stage 1 and stage 2 analyses. We
obtained overall combined significance levels across all the three stages using a
fixed-effects meta-analysis, using a threshold of Po5.0 10 8 to denote genome-
wide significance. For each novel locus, we examined evidence of departure from a
log-additive (multiplicative) model to assess any genotype-specific effect. Using
stage 3 data, individual genotype data ORs were calculated for heterozygote (ORhet)
and homozygote (ORhom) genotypes, which were compared with the per-allele
ORs. We tested for a difference in these 1 d.f. and 2 d.f. logistic regression models
to assess for evidence of deviation (Po0.05) from a log-additive model. Using stage
1 data, we examined for statistical interaction between the four new loci and the
existing 21 TGCT predisposition loci by evaluating the effect of adding an
interaction term to the regression model, adjusted for stage, using a likelihood ratio
test (using a significance threshold of Po5.95 10 4 to account for 84 tests). LD
blocks were defined using the HapMap recombination rates (cM/Mb) and defined
using the Oxford recombination hotspots55. Regional plots were generated
using visPIG software56. PRSs were constructed using methods established by
Pharoah et al.57, based on a log-normal distribution LN (m, s2) with mean m and
variance s2 (that is, relative risk is normally distributed on a logarithmic scale).
Lifetime TGCT risk was based on 2014 CRUK lifetime incidence rate of 0.5%
(ref. 58), multiplied by RR to give lifetime risk per percentile of the PRS.
Competing mortality risk analysis was not conducted as over three quarters of
TGCT cases present at ages 45 years and younger58, for whom cumulative
mortality risk from all other causes is only 3.6% (ref. 59).
Imputation. Genome-wide imputation was performed using the genotyped data
from stage 1. The 1000 genomes phase 1 data (September 13 release) was used as a
reference panel, with haplotypes pre-phased using SHAPEIT2 (ref. 60). Imputation
was performed using IMPUTE2 software61 and association between imputed
genotype and TGCT was tested using SNPTEST62, under a frequentist model of
association. QC was performed on the imputed SNPs; excluding those with INFO
score o0.8 and MAF o0.01.
Functional annotation. We used data from the ENCODE project and HaploReg20
to investigate for evidence of transcriptional regulation at our identified locus to
assess (i) whether the variant resides in a region in which modification of histone
proteins is suggestive of enhancer and other regulatory activity (H3K4Me1 and
H3K27A histone modification) or promoter activity (H3K4Me3 histone
modification), (ii) whether the variant lies in a region where the chromatin is
hypersensitive to cutting by the DNase enzyme (suggestive of regulatory region),
(iii) whether the variant lies in a region of binding of transcription factor proteins
(as assayed by chromatin immunoprecipitation with antibodies specific to the
transcription factor followed by sequencing of the precipitated DNA (ChIP-seq)),
(iv) whether the variant affects a specific regulatory motif, as evaluated from
position weighted matrices assembled from TRANSFAC, JASPAR and protein-
binding microarray experiments.
We investigated for evidence of association between the SNPs at our locus and
changes in gene expression using publicly available cancer genome atlas RNAseq
and Affymetrix 6.0 SNP/exome sequencing data (http://cancergenome.nih.gov/).
Where genotype data for our sentinel SNP was not available, we selected the top
two closest proxy SNPs available in the combined SNP/exome data sets, based on
highest r2 value. Associations between normalized RNA counts per gene and
genotype were quantified using the Kruskal–Wallis trend test. A total of 18 tests
were performed, hence a P value threshold of 0.0028 was considered significant to
correct for multiple testing.
Pathway analysis. Pathway enrichment analysis was conducted using the
Improved Gene Set Enrichment Analysis for genome-wide association study
(i-GSEA4GWASv1.1; ref. 26). Predefined biological pathways and processes
including KEGG, reactome pathways and gene ontology gene sets (GO) were
assessed for association with TGCT. SNPs within a ±5 kb distance were mapped
to genes and the maximum  log(P value) of all the SNPs mapped to a gene was
used to represent the gene, using SNP label permutation.
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